-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 24, Haizheng Pharmaceuticals announced that its controlling subsidiary, Haizheng Pfizer, had received a "Drug Supplemental Application Approval" for the CFDA approved the issuance of minotin hydrochloride capsules, agreed to the transfer of Wyeth Pharmaceuticals' production technology for the product to Haizheng Pfizer, and issued a drug approval number, while withdrawing Wyeth Pharmaceuticals' drug approval number for that variety. The above products cover two specifications, including 50mg and 100mg, and the drug approval number is valid until 11 September 2022.original research products sold in China more than 100 million yuan
hydrochloric acid micycline capsules are mainly applicable to staphylococcus, streptococcus, pneumococcus, gonorrhoea, dysentery, E. coli, Crebb's bacteria, Physicles, Eococcus Treatment of inflammation such as vasculitis, superficial purulent infection, deep septic disease, bronchitis, pneumonia, otitis media, dysentery, enteritis, bileitis, gallbladderitis, septic disease, bacteremia, etc. caused by syphilis helix and chlamydia.according to
-meter intranet data, hydrochloric acid micycline capsules ranked third in 2016 in the top 20 for chemical tyrencline products in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions). Wyeth Pharmaceuticals, the manufacturer, has a market share of 88.86 percent, and in 2016, china's urban retail pharmacies ranked second in the top 20 chemical products TOP20, the original research manufacturer Wyeth Pharmaceuticals accounted for 99.93 percent of the market share.'s performance has been sluggish for years
in recent years, Haizheng Pharmaceuticals' operating income has been impressive, but its net profit has been poor, including a negative net profit in 2016.
Haizheng Pharmaceuticals said in its 2016 annual report that the company's performance in recent years continued to decline significantly and the main reasons for the loss include: by the United States FDA and the European Union EMA on the company's product import ban, resulting in some exports to the United States, the European Union and other pharmaceutical markets of the API business revenue in addition, due to Pfizer's plant in Italy due to the impact of production facilities and other issues, resulting in tight supply in the global market, 2015 began to appear under-supply, reducing the company's 2015-2016 operating income.
first half of 2017, Haizhengtai base successfully passed the FDA inspection, the original ban on entry into the United States of products were all released by the FDA, product sales have resumed. Haizheng Pfizer has completed the preparation of the full return of Tejixing sales, the second half of the year will be all-round special star re-listing work. Overall performance in 2017 is expected to be better than last year.the results of technology transfer in drug production, Haizheng Pharmaceuticals added star products
hydrochloric acid minotin capsules of the original research technology manufacturer for Wyeth Pharmaceuticals, a subsidiary of Pfizer Pharmaceuticals.
is understood that Haizheng Pfizer submitted an application to the CFDA in July 2015 for the transfer of pharmaceutical technology for the production of minotin hydrochloride capsules, and in October 2017 obtained a technology transfer approval for the production of minotin hydrochloride capsules, which will retain the "Full" product name.
Haizheng Pharmaceuticals said in a statement that the transfer of the drug technology transfer is the transfer of hydrochloric acid minotin capsule original research technology from Wyeth Pharmaceuticals to Haizheng Pfizer Fuyang plant, meaning that Haizheng Pfizer already owns the production rights and ownership of the drug, the future will further enhance the company's product value chain. (Minnet Original)